Part 1: An open label pilot study to determine interstitial and tissue concentrations of aliskiren and effects on the renin- angiotensin system (RAS) in fat and skeletal muscle of hypertensive patients with abdominal obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity.

Trial Profile

Part 1: An open label pilot study to determine interstitial and tissue concentrations of aliskiren and effects on the renin- angiotensin system (RAS) in fat and skeletal muscle of hypertensive patients with abdominal obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine
  • Indications Hypertension; Obesity
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jul 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 03 May 2012 Actual patient number added 26 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top